RPG Life Sciences Limited — Updates, 25-07-2025: Press Release

RPG Life Sciences (RPGLIFE) reported Q1 FY26 financial results. Revenue increased 2.1% YoY to Rs. 168.9 Cr, up from Rs. 165.4 Cr. Profit before tax was Rs. 35.4 Cr, largely in line with last year, while EBITDA margin stood healthy at 24.1%. Management highlighted sustained sales momentum, with Domestic Formulations driving market-beating growth. The company is set to accelerate International Formulations and API segments by onboarding new customers, expanding into new markets, and launching new molecules. RPGLIFE is also actively exploring inorganic growth avenues across formulations and APIs to boost its growth trajectory.